Advertisement Pharmaceutical Business review - Page 192 of 5267 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
April 7, 2026

Neurocrine to acquire Soleno in $2.9bn transaction

Neurocrine Biosciences has signed a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash, which represents $2.9bn in total transaction equity value.

Soleno’s lead product Vykat XR is intended for Prader-Willi syndrome. Credit: Yuriy K / Shutterstock.com.